Labs / ADME, DMPK & toxicology

SciRhom GmbH
Martinsried, Germany · scirhom.com
On your own
Free. Their own form.
Through Midgard
Midgard sends your request to the lab and keeps the order's messages, papers and payments in one place. Free to ask. 1% platform fee if you keep the order on Midgard.
SciRhom GmbH develops iRhom2-targeting antibody therapies for autoimmune diseases and related indications. It is based in Munich, Germany, and is advancing its lead program SR-878 through clinical development. The company works on the TACE/ADAM17 pathway and has collaborated with the Medical University of Vienna and Prof. Carl Blobel of the Hospital for Special Surgery in New York City.
They take quote requests by email.
What they offer
iRhom2-targeting therapeutic development
Develops proprietary and first-in-class iRhom2-targeting therapies for autoimmune diseases and other indications.
Therapeutic antibody development
Develops humanized antibodies against iRhom2 with the aim of modulating TACE/ADAM17-controlled inflammatory pathways.
Clinical study execution for SR-878
Conducts a first-in-human, double-blind, placebo-controlled, single ascending dose study of SR-878 in healthy volunteers.
What they work on
- Modalities
- Small molecule, Antibody
- Species and models
- mouse models of rheumatoid arthritis, mouse models of inflammatory bowel disease, healthy volunteers
- Scale and capacity
- up to 48 healthy volunteers
- Therapeutic areas
- autoimmune diseases, rheumatoid arthritis, inflammatory bowel disease, lupus nephritis
- Turnaround
- study expected to read out in H2 2025
- Sites
- Munich, Germany · Vienna, Austria · New York City, USA
- Serves
- Germany, Austria, USA
- Founded
- 2016
Similar labs. Bioklone Biotech Private Limited, Oncodesign Services, Sparx BIO, Veloxity Labs
Found in a contract services directory. Listing built from scirhom.com. Work here? Claim this listing.